FDA Seeks Comments on Potential Marijuana Reclassification

OMA Connections Partner, Jackson Lewis, posted: “The Food and Drug Administration requested comments in a notice published in the Federal Register on April 9, 2018 concerning the “abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use” of five marijuana-related substances: cannabis plant and resin; extracts and tinctures of cannabis; delta-9-tetrahydrocannabinol (THC); stereoisomers of THC; and cannabidiol (CBD). The comments will be considered in preparing a response from the United States to the World Health Organization (WHO)’s request for information regarding “the legitimate use, harmful use, status of national control and potential impact of international control” for each of these substances. …

“Any change in marijuana’s classification under international drug control treaties may influence the way marijuana is classified in the United States. Employers who are opposed to marijuana legalization should consider submitting comments.”

More here. 4/25/2018